This indicates that PD-L1 expression on A20 leukemia cells confers a survival advantage to the tumor probably by inhibiting either the NK cell-mediated response or the CD8 T-cell-mediated response, the two immune cell contributors to hybrid resistance against the tumor. The gene discussed is CD274; the disease is leukemia.